Biotechnology markets for bioconjugation and biosimulation projected to grow

The global bioconjugation and biosimulation markets are projected to experience significant growth driven by advancements in biotechnology and pharmaceutical research.

The bioconjugation market is expected to grow at a compound annual growth rate (CAGR) of 13% over the next five years. This growth is fueled by increasing demand for targeted therapeutics, such as antibody–drug conjugates (ADCs), and innovations in precision medicine and diagnostics. While technological advancements and biotech investment drive the sector, high manufacturing costs and regulatory complexities remain challenges.

Simultaneously, the biosimulation market is forecasted to expand from approximately USD 4.27 billion in 2026 to USD 9.24 billion by 2031, representing a CAGR of 16.7%. The industry is increasingly adopting computational methods, including artificial intelligence and model-informed drug development, to optimize clinical trials and reduce R&D costs. North America currently holds a dominant market share, while the Asia-Pacific region is expected to be the fastest-growing market.